Skip to content
Screener

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$534M+11.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.96B+0.8%
Amgen logo
AmgenAMGN
$1.11B-17.1%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$107K-6.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$79K+2.6%

Segments

By product

See full
Other Research And Development$800K-11.1%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$681.93M+1,826%
Enterprise value$621.3M-5,241%
P/S681.9×+670×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss$(29,919)$(26,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation5,1483,611
Depreciation1,7421,865
Non-cash operating lease expense(417)241
Net accretion of investments(243)(1)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(561)2,020

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s D&A?
Shattuck Labs, Inc. (STTK) reported D&A of $851K in Q2 2026.
How has Shattuck Labs, Inc.'s D&A changed year-over-year?
Shattuck Labs, Inc.'s D&A decreased by 8.4% year-over-year, from $929K to $851K.
What is the long-term trend for Shattuck Labs, Inc.'s D&A?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s D&A has grown at a 27.9% compound annual growth rate (CAGR), from $1.38M to $3.69M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Shattuck Labs, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude